Checkpoint Inhibitor Side Effect: Study May Reveal Cause
Cancer treatment’s Hidden Cost: Study Reveals Why Some Patients Become More Susceptible to infections
New research sheds light on why some cancer patients receiving a revolutionary immunotherapy experience a higher risk of infections.
Checkpoint inhibitors have transformed cancer treatment by unleashing the immune system’s power to fight tumors. However, this breakthrough therapy comes with a potential downside: an increased susceptibility to common infections in about 20% of patients.
A new study published in Immunity offers crucial insights into this phenomenon. Researchers,led by Dr. Stuart Tangye of the University of New South Wales Sydney and the garvan Institute of Medical Research, discovered that while checkpoint inhibitors boost the immune system’s ability to attack cancer cells, they may also hinder the function of memory B cells. These vital cells are responsible for producing antibodies that protect against infections.
“Our findings indicate that checkpoint inhibitors,while effective against cancer,can handicap B cells,making it harder for the body to generate high-quality antibodies against common pathogens,” explained Dr. tangye.
Unveiling the Mechanism: A Look at Rare Genetic Deficiencies
The research team examined immune cells in patients with rare genetic deficiencies in PD-1 or its binding partner PD-L1, as well as in animal models lacking PD-1 signaling. They found that impaired or absent PD-1 activity led to a reduction in the diversity and quality of antibodies produced by memory B cells.
“We found that individuals born with a deficiency in PD-1 or PD-L1 have reduced diversity in their antibodies and fewer memory B cells, making it harder to generate effective antibodies against viruses and bacteria,” said lead study author Dr. Masato Ogishi of Rockefeller University.
This dampening effect on memory B cells could explain the increased infection rates observed in cancer patients receiving checkpoint inhibitor therapy.
Balancing Act: Boosting Anti-Tumor Immunity While Protecting Against Infections
The study highlights a delicate balance: PD-1 inhibition enhances anti-tumor immunity but simultaneously weakens B-cell immunity.
“PD-1 inhibition has a ‘yin and yang’ nature,” noted co-study author Dr.Kenji Chamoto of Kyoto University. “It activates antitumor immunity but simultaneously occurring impedes B-cell immunity.This duality seems to stem from a conserved mechanism of immune homeostasis.”
Looking Ahead: Strategies for minimizing Infection Risk
The findings underscore the need for clinicians to closely monitor B-cell function in patients receiving checkpoint inhibitors.
“Although PD-1 inhibitors have greatly improved cancer care, our findings indicate that clinicians need to be aware of the potential trade-off between enhanced antitumor immunity and impaired antibody-mediated immunity,” emphasized co-senior study author Dr. Stéphanie Boisson-Dupuis of Rockefeller University.
One potential solution is immunoglobulin replacement therapy, a treatment used to replace missing antibodies in patients with immunodeficiencies. This could be considered as a preventative measure for cancer patients at higher risk of infections.
The researchers are now exploring strategies to refine checkpoint inhibitor treatments, aiming to maintain their powerful anticancer effects while preserving the immune system’s ability to fight infections.”This research highlights the potential for cancer, genomics, and immunology research to inform one another, enabling discoveries that can benefit the broader population,” concluded Dr. Tangye.
Checkpoint Inhibitors: Unleashing Immunity But at What Cost?
New York, NY – Immunotherapy has revolutionized cancer treatment, but a new study reveals a hidden cost: heightened susceptibility to infections in some patients.
While checkpoint inhibitors,a transformative immunotherapy,empower the immune system to fight cancer cells,they may inadvertently suppress the function of memory B cells. These crucial cells produce antibodies that shield against infections.
dr. Stuart tangye of the University of New South Wales Sydney and the Garvan Institute of Medical Research, who led the study published in Immunity, explains, “Our findings indicate that checkpoint inhibitors, while effective against cancer, can handicap B cells, making it harder for the body to generate high-quality antibodies against common pathogens.”
The study delved into the mechanics of this phenomenon by investigating immune cells in patients with rare genetic deficiencies in PD-1 or PD-L1 – checkpoints targeted by these inhibitors. Animal models lacking PD-1 signaling were also analyzed.
Lead study author Dr. Masato Ogishi of Rockefeller University, highlighted the study’s findings: “We found that individuals born with a deficiency in PD-1 or PD-L1 have reduced diversity in their antibodies and fewer memory B cells, making it harder to generate effective antibodies against viruses and bacteria.”
This suppression of memory B cells potentially explains the increased infection rates observed in cancer patients undergoing checkpoint inhibitor therapy.
the study underscores a delicate balance: PD-1 inhibition strengthens anti-tumor immunity but simultaneously weakens B-cell immunity.
co-study author Dr.Kenji Chamoto of Kyoto University,describes this phenomenon as a “yin and yang” nature. “It activates antitumor immunity but simultaneously impedes B-cell immunity.This duality seems to stem from a conserved mechanism of immune homeostasis.”
Dr. Stéphanie Boisson-Dupuis of rockefeller University,a co-senior study author,emphasizes the need for closer monitoring of B-cell function in patients receiving checkpoint inhibitors.“Although PD-1 inhibitors have greatly improved cancer care, our findings indicate that clinicians need to be aware of the potential trade-off between enhanced antitumor immunity and impaired antibody-mediated immunity.”
The researchers are exploring strategies to refine these treatments, aiming to preserve the powerful anticancer effects while safeguarding the immune system’s ability to combat infections. One potential solution: immunoglobulin replacement therapy to replenish missing antibodies in high-risk patients.
This research exemplifies the benefits of cross-disciplinary research, demonstrating how insights from cancer, genomics, and immunology can benefit not only cancer patients but the broader population.